发布求助
文献互助 智能选刊 最新文献

Nature Reviews. Drug Discovery最新文献

筛选
英文 中文
Ramping up mitochondrial DNA replication 加快线粒体DNA的复制
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/d41573-025-00079-x
Katie Kingwell
{"title":"Ramping up mitochondrial DNA replication","authors":"Katie Kingwell","doi":"10.1038/d41573-025-00079-x","DOIUrl":"10.1038/d41573-025-00079-x","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 6","pages":"419-419"},"PeriodicalIF":101.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1-based therapies for diabetes, obesity and beyond 以glp -1为基础的糖尿病、肥胖症及其他疾病的治疗
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-25 DOI: 10.1038/s41573-025-01183-8
Daniel J. Drucker
{"title":"GLP-1-based therapies for diabetes, obesity and beyond","authors":"Daniel J. Drucker","doi":"10.1038/s41573-025-01183-8","DOIUrl":"10.1038/s41573-025-01183-8","url":null,"abstract":"Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality. The success of these medicines has spurred development of next-generation GLP-1-based drugs, promising greater weight loss, improved tolerability and additional options for the route and frequency of dosing. This Review profiles established and emerging GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects. Structurally unique GLP-1-based medicines that achieve substantially greater and rapid weight loss may impact musculoskeletal health, providing a rationale for therapeutics that more selectively target adipose tissue loss while preserving muscle mass and strength. Ongoing clinical trials in peripheral vascular disease, neuropsychiatric and substance use disorders, metabolic liver disease, arthritis, hypertension and neurodegenerative disorders may broaden indications for GLP-1-based therapeutics.  GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based medicines, focusing on novel GLP-1 receptor agonists and GLP-1-based multi-agonists. Considerations and challenges in the development of GLP-1-based therapies and potential future indications are discussed.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 8","pages":"631-650"},"PeriodicalIF":101.8,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New antifungal tackles drug-resistant infections 新的抗真菌药物治疗耐药感染
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-24 DOI: 10.1038/d41573-025-00074-2
Sarah Crunkhorn
{"title":"New antifungal tackles drug-resistant infections","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-025-00074-2","DOIUrl":"10.1038/d41573-025-00074-2","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 6","pages":"418-418"},"PeriodicalIF":101.8,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China 加快药品上市注册程序对中国新药审批的影响
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-23 DOI: 10.1038/d41573-025-00070-6
Yingge Gu,  Ran Jing,  Kenneth I. Kaitin,  Liming Shao
{"title":"The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China","authors":"Yingge Gu, \u0000 Ran Jing, \u0000 Kenneth I. Kaitin, \u0000 Liming Shao","doi":"10.1038/d41573-025-00070-6","DOIUrl":"10.1038/d41573-025-00070-6","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 7","pages":"492-493"},"PeriodicalIF":101.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/d41573-025-00070-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels 塑造未来的二级药理学小组：发展安全小组的目标选择标准
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-22 DOI: 10.1038/s41573-025-01184-7
Friedemann Schmidt, Richard J. Brennan, Steve Jenkinson, Jean-Pierre Valentin
{"title":"Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels","authors":"Friedemann Schmidt, Richard J. Brennan, Steve Jenkinson, Jean-Pierre Valentin","doi":"10.1038/s41573-025-01184-7","DOIUrl":"10.1038/s41573-025-01184-7","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 6","pages":"482-484"},"PeriodicalIF":101.8,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enzymes in secondary pharmacology screening panels: is there room for improvement? 二级药理学筛选组中的酶：还有改进的空间吗？
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-22 DOI: 10.1038/s41573-025-01173-w
Monika Maciag, Vardan T. Karamyan
{"title":"Enzymes in secondary pharmacology screening panels: is there room for improvement?","authors":"Monika Maciag, Vardan T. Karamyan","doi":"10.1038/s41573-025-01173-w","DOIUrl":"10.1038/s41573-025-01173-w","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 6","pages":"480-481"},"PeriodicalIF":101.8,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation 芳烃受体：治疗性免疫调节的修复靶点
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-17 DOI: 10.1038/s41573-025-01172-x
Carolina M. Polonio, Kimberly A. McHale, David H. Sherr, David Rubenstein, Francisco J. Quintana
{"title":"The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation","authors":"Carolina M. Polonio, Kimberly A. McHale, David H. Sherr, David Rubenstein, Francisco J. Quintana","doi":"10.1038/s41573-025-01172-x","DOIUrl":"10.1038/s41573-025-01172-x","url":null,"abstract":"The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor originally identified as the target mediating the toxic effects of environmental pollutants including polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs) and dioxins. For years, AHR activation was actively avoided during drug development. However, the AHR was later identified as an important physiological regulator of the immune response. These findings triggered a paradigm shift that resulted in identification of the AHR as a regulator of both innate and adaptive immunity and outlined a pathway for its modulation by the diet, commensal flora and metabolism in the context of autoimmunity, cancer and infection. Moreover, the AHR was revealed as a candidate target for the therapeutic modulation of the immune response. Indeed, the first AHR-activating drug (tapinarof) was recently approved for the treatment of psoriasis. Clinical trials are underway to evaluate the effects of tapinarof and other AHR-targeting therapeutics in inflammatory diseases, cancer and infections. This Review outlines the molecular mechanism of AHR action, and describes how it regulates the immune response. We also discuss links to disease and AHR-targeting therapeutics that have been tested in past and ongoing clinical trials. The aryl hydrocarbon receptor (AHR) mediates the toxic effects of environmental pollutants and regulates innate and adaptive immune responses. This Review discusses how, in the past, AHR activation was avoided during drug development, but now the AHR is being targeted for treating inflammation, cancer and infectious diseases.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 8","pages":"610-630"},"PeriodicalIF":101.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Back to the drawing board for anhedonia drugs 重新开始治疗快感缺乏症的药物
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-16 DOI: 10.1038/d41573-025-00073-3
Asher Mullard
{"title":"Back to the drawing board for anhedonia drugs","authors":"Asher Mullard","doi":"10.1038/d41573-025-00073-3","DOIUrl":"10.1038/d41573-025-00073-3","url":null,"abstract":"Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders. Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 5","pages":"319-320"},"PeriodicalIF":101.8,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Back to therapeutic modality basics 回到治疗模式的基础
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-16 DOI: 10.1038/d41573-025-00072-4
Asher Mullard
{"title":"Back to therapeutic modality basics","authors":"Asher Mullard","doi":"10.1038/d41573-025-00072-4","DOIUrl":"10.1038/d41573-025-00072-4","url":null,"abstract":"Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA. Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 5","pages":"327-328"},"PeriodicalIF":101.8,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/d41573-025-00072-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA new drug approvals in Q1 2025 2025年第一季度FDA新药批准
IF 101.8 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2025-04-14 DOI: 10.1038/d41573-025-00071-5
Paul Verdin
{"title":"FDA new drug approvals in Q1 2025","authors":"Paul Verdin","doi":"10.1038/d41573-025-00071-5","DOIUrl":"10.1038/d41573-025-00071-5","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 5","pages":"324-324"},"PeriodicalIF":101.8,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/d41573-025-00071-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信